BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Konukiewitz B, Jesinghaus M, Steiger K, Schlitter AM, Kasajima A, Sipos B, Zamboni G, Weichert W, Pfarr N, Klöppel G. Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3. Hum Pathol 2018;77:70-9. [PMID: 29596894 DOI: 10.1016/j.humpath.2018.03.018] [Cited by in Crossref: 47] [Cited by in F6Publishing: 35] [Article Influence: 11.8] [Reference Citation Analysis]
Number Citing Articles
1 Chen K, Zhang W, Zhang Z, He Y, Liu Y, Yang X. Simple Vascular Architecture Classification in Predicting Pancreatic Neuroendocrine Tumor Grade and Prognosis. Dig Dis Sci 2018;63:3147-52. [DOI: 10.1007/s10620-018-5240-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
2 Washington MK, Goldberg RM, Chang GJ, Limburg P, Lam AK, Salto-Tellez M, Arends MJ, Nagtegaal ID, Klimstra DS, Rugge M, Schirmacher P, Lazar AJ, Odze RD, Carneiro F, Fukayama M, Cree IA; WHO Classification of Tumours Editorial Board. Diagnosis of digestive system tumours. Int J Cancer 2021;148:1040-50. [PMID: 32674220 DOI: 10.1002/ijc.33210] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
3 Faias S, Prazeres S, Cunha M, Pereira L, Roque R, Chaves P, Cravo M, Claro I, Silveira M, Leite V, Dias Pereira A. Chromogranin A and NSE in cystic pancreatic neuroendocrine tumors. Clin Res Hepatol Gastroenterol 2021;45:101601. [PMID: 33386244 DOI: 10.1016/j.clinre.2020.101601] [Reference Citation Analysis]
4 Wong NACS. My approach to endoscopic ultrasound-guided fine-needle aspiration biopsy specimens of the pancreas. J Clin Pathol 2020;73:297-309. [PMID: 31964682 DOI: 10.1136/jclinpath-2019-206331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Uccella S, La Rosa S, Metovic J, Marchiori D, Scoazec JY, Volante M, Mete O, Papotti M. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocr Pathol 2021;32:192-210. [PMID: 33433884 DOI: 10.1007/s12022-020-09660-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 12.0] [Reference Citation Analysis]
6 Romano D. Relevance of neuroendocrine tumours models assessed by kinomic profiling. Ann Endocrinol (Paris) 2019;80:144-8. [PMID: 31054767 DOI: 10.1016/j.ando.2019.04.008] [Reference Citation Analysis]
7 Príncipe C, Dionísio de Sousa IJ, Prazeres H, Soares P, Lima RT. LRP1B: A Giant Lost in Cancer Translation. Pharmaceuticals (Basel) 2021;14:836. [PMID: 34577535 DOI: 10.3390/ph14090836] [Reference Citation Analysis]
8 Holmager P, Langer SW, Federspiel B, Willemoe GL, Garbyal RS, Melchior L, Klose M, Kjaer A, Hansen CP, Andreassen M, Knigge U. Increase of Ki-67 index and influence on mortality in patients with neuroendocrine neoplasms. J Neuroendocrinol 2021;33:e13018. [PMID: 34414612 DOI: 10.1111/jne.13018] [Reference Citation Analysis]
9 Zhang MY, He D, Zhang S. Pancreatic neuroendocrine tumors G3 and pancreatic neuroendocrine carcinomas: Differences in basic biology and treatment. World J Gastrointest Oncol 2020; 12(7): 705-718 [PMID: 32864039 DOI: 10.4251/wjgo.v12.i7.705] [Cited by in CrossRef: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Pelosi G, Bianchi F, Dama E, Metovic J, Barella M, Sonzogni A, Albini A, Papotti M, Gong Y, Vijayvergia N. A Subset of Large Cell Neuroendocrine Carcinomas in the Gastroenteropancreatic Tract May Evolve from Pre-existing Well-Differentiated Neuroendocrine Tumors. Endocr Pathol 2021;32:396-407. [PMID: 33433886 DOI: 10.1007/s12022-020-09659-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
11 Bräutigam K, Rodriguez-Calero A, Kim-Fuchs C, Kollár A, Trepp R, Marinoni I, Perren A. Update on Histological Reporting Changes in Neuroendocrine Neoplasms. Curr Oncol Rep 2021;23:65. [PMID: 33855635 DOI: 10.1007/s11912-021-01062-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Asa SL, Mete O, Cusimano MD, McCutcheon IE, Perry A, Yamada S, Nishioka H, Casar-Borota O, Uccella S, La Rosa S, Grossman AB, Ezzat S; Attendees of the 15th Meeting of the International Pituitary Pathology Club, Istanbul October 2019. Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol 2021;34:1634-50. [PMID: 34017065 DOI: 10.1038/s41379-021-00820-y] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Arakelyan J, Zohrabyan D, Philip PA. Molecular profile of pancreatic neuroendocrine neoplasms (PanNENs): Opportunities for personalized therapies. Cancer 2021;127:345-53. [PMID: 33270905 DOI: 10.1002/cncr.33354] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
14 Jungels C, Deleporte A. State of the art and future directions in the systemic treatment of neuroendocrine neoplasms. Curr Opin Oncol 2021;33:378-85. [PMID: 33973550 DOI: 10.1097/CCO.0000000000000740] [Reference Citation Analysis]
15 Kasajima A, Konukiewitz B, Schlitter AM, Weichert W, Klöppel G. An analysis of 130 neuroendocrine tumors G3 regarding prevalence, origin, metastasis, and diagnostic features. Virchows Arch 2021. [PMID: 34499237 DOI: 10.1007/s00428-021-03202-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kang XN, Zhang XY, Bai J, Wang ZY, Yin WJ, Li L. Analysis of B-ultrasound and contrast-enhanced ultrasound characteristics of different hepatic neuroendocrine neoplasm. World J Gastrointest Oncol 2019; 11(5): 436-448 [PMID: 31139313 DOI: 10.4251/wjgo.v11.i5.436] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
17 Agaimy A, Stoehr R, Otto M, Bräsen JH, Pfarr N, Konukiewitz B, Kasajima A, Hartmann A, Klöppel G. Intra-abdominal EWSR1/FUS-CREM-rearranged malignant epithelioid neoplasms: two cases of an emerging aggressive entity with emphasis on misleading immunophenotype. Virchows Arch 2021. [PMID: 34228212 DOI: 10.1007/s00428-021-03140-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Luan Z, Morimoto Y, Fushimi A, Yamashita N, Suo W, Bhattacharya A, Hagiwara M, Jin C, Kufe D. MUC1-C Dictates Neuroendocrine Lineage Specification in Pancreatic Ductal Adenocarcinomas. Carcinogenesis 2021:bgab097. [PMID: 34657147 DOI: 10.1093/carcin/bgab097] [Reference Citation Analysis]
19 Faias S, Duarte M, Pereira L, Chaves P, Cravo M, Dias Pereira A, Albuquerque C. Methylation changes at the GNAS imprinted locus in pancreatic cystic neoplasms are important for the diagnosis of malignant cysts. World J Gastrointest Oncol 2020; 12(9): 1056-1064 [PMID: 33005298 DOI: 10.4251/wjgo.v12.i9.1056] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Konukiewitz B, Jesinghaus M, Kasajima A, Klöppel G. Neuroendocrine neoplasms of the pancreas: diagnosis and pitfalls. Virchows Arch 2021. [PMID: 34647171 DOI: 10.1007/s00428-021-03211-5] [Reference Citation Analysis]
21 Worth PJ, Leal J, Ding Q, Trickey A, Dua MM, Chatzizacharias N, Soonawalla Z, Athanasopoulos P, Toumpanakis C, Hansen P, Parks RW, Connor S, Parker K, Koea J, Srinavasa S, Ielpo B, Vicente Lopez E, Lawrence B, Visser BC; International Pancreatic Neuroendocrine Tumor Study Group. Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesions. HPB (Oxford) 2020;22:1359-67. [PMID: 32081540 DOI: 10.1016/j.hpb.2019.12.014] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Klöppel G. [Neuroendocrine neoplasms : Two families with distinct features unified in one classification (German version)]. Pathologe 2019;40:211-9. [PMID: 30969346 DOI: 10.1007/s00292-019-0594-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Ishida S, Akita M, Fujikura K, Komatsu M, Sawada R, Matsumoto H, Saegusa J, Itoh T, Kakeji Y, Zen Y. Neuroendocrine carcinoma and mixed neuroendocrine‒non-neuroendocrine neoplasm of the stomach: a clinicopathological and exome sequencing study. Hum Pathol 2021;110:1-10. [PMID: 33359239 DOI: 10.1016/j.humpath.2020.12.008] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
24 April-Monn SL, Andreasi V, Schiavo Lena M, Sadowski MC, Kim-Fuchs C, Buri MC, Ketkar A, Maire R, Di Domenico A, Schrader J, Muffatti F, Doglioni C, Partelli S, Falconi M, Perren A, Marinoni I. EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers (Basel) 2021;13:5014. [PMID: 34638497 DOI: 10.3390/cancers13195014] [Reference Citation Analysis]
25 Kim H, An S, Lee K, Ahn S, Park DY, Kim JH, Kang DW, Kim MJ, Chang MS, Jung ES, Kim JM, Choi YJ, Jin SY, Chang HK, Cho MY, Kang YK, Kang M, Ahn S, Kim YW, Hong SM; Gastrointestinal Pathology Study Group of the Korean Society of Pathologists. Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study. Cancer Res Treat 2020;52:263-76. [PMID: 31319641 DOI: 10.4143/crt.2019.192] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
26 Gao HL, Wang WQ, Yu XJ, Liu L. Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. Exp Hematol Oncol 2020;9:28. [PMID: 33101770 DOI: 10.1186/s40164-020-00184-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
27 Tanaka H, Hijioka S, Hosoda W, Ueno M, Kobayashi N, Ikeda M, Ito T, Kodama Y, Morizane C, Notohara K, Taguchi H, Kitano M, Komoto I, Tsuji A, Hashigo S, Kanno A, Miyabe K, Takagi T, Ishii H, Kojima Y, Yoshitomi H, Yanagimoto H, Furuse J, Mizuno N. Pancreatic neuroendocrine carcinoma G3 may be heterogeneous and could be classified into two distinct groups. Pancreatology 2020;20:1421-7. [PMID: 32891532 DOI: 10.1016/j.pan.2020.07.400] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
28 Mei W, Ding Y, Wang S, Jia Y, Cao F, Li F. Head and body/tail pancreatic neuroendocrine tumors have different biological characteristics and clinical outcomes. J Cancer Res Clin Oncol 2020;146:3049-61. [PMID: 32601815 DOI: 10.1007/s00432-020-03303-w] [Reference Citation Analysis]
29 Gill AJ. Why did they change that? Practical implications of the evolving classification of neuroendocrine tumours of the gastrointestinal tract. Histopathology 2021;78:162-70. [PMID: 33382490 DOI: 10.1111/his.14172] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Tong Z, Wang L, Shi W, Zeng Y, Zhang H, Liu L, Zheng Y, Chen C, Xia W, Fang W, Zhao P. Clonal Evolution Dynamics in Primary and Metastatic Lesions of Pancreatic Neuroendocrine Neoplasms. Front Med (Lausanne) 2021;8:620988. [PMID: 34026777 DOI: 10.3389/fmed.2021.620988] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Chen MH, Chou WC, Hsiao CF, Jiang SS, Tsai HJ, Liu YC, Hsu C, Shan YS, Hung YP, Hsich CH, Chiu CH, Liu TC, Cho SF, Liu TW, Chao Y. An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy of TLC388 and Genomic Analysis for Poorly Differentiated Neuroendocrine Carcinomas. Oncologist 2020;25:e782-8. [PMID: 31852810 DOI: 10.1634/theoncologist.2019-0490] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Jiang R, Hong X, Zhao Y, Wu W. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms. Cancer Lett 2021;499:39-48. [PMID: 33246093 DOI: 10.1016/j.canlet.2020.11.012] [Reference Citation Analysis]
33 Chen X, Guo C, Cui W, Sun K, Wang Z, Chen X. CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms. Cancer Manag Res 2020;12:4625-31. [PMID: 32606955 DOI: 10.2147/CMAR.S250071] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
34 Boons G, Vandamme T, Peeters M, Van Camp G, Op de Beeck K. Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies. Rev Endocr Metab Disord 2019;20:333-51. [DOI: 10.1007/s11154-019-09508-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
35 Scoazec JY. Lung and digestive neuroendocrine neoplasms. From WHO classification to biomarker screening: Which perspectives? Ann Endocrinol (Paris) 2019;80:163-5. [PMID: 31064659 DOI: 10.1016/j.ando.2019.04.011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]